此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

在肿瘤完全切除后,在 ctDNA 阳性或具有高危病理特征的 I 期腺癌 NSCLC 受试者中进行 Dato-DXd 辅助疗法联合 Rilvegostomig 或 Rilvegostomig 单药疗法与标准护理的 III 期随机研究 (TROPION-Lung12)

2026年9月22日 更新者:AstraZeneca

在 I 期腺癌非小细胞肺癌受试者中,在肿瘤完全切除后,辅助 Datopotamab Deruxtecan (Dato-DXd) 联合 Rilvegostomig 或 Rilvegostomig 单药疗法与标准护理的 III 期、随机、开放标签全球研究谁是 ctDNA 阳性或具有高风险病理特征 (TROPION-Lung12)

This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.

研究概览

详细说明

The primary objective of the study is to assess the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig relative to SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.

研究类型

介入性

注册 (实际的)

25

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Nova Scotia
      • Halifax、Nova Scotia、加拿大、B3H 2Y9
        • Research Site
    • Ontario
      • Oshawa、Ontario、加拿大、L1G 2B9
        • Research Site
    • Quebec
      • Montreal、Quebec、加拿大、H2X 3J4
        • Research Site
      • Kaohsiung City、台湾、80756
        • Research Site
      • Taipei、台湾、10002
        • Research Site
      • Taipei、台湾、112
        • Research Site
      • Taipei、台湾、114
        • Research Site
      • Taoyuan、台湾、333
        • Research Site
      • Ankara、土耳其(türkiye)、06280
        • Research Site
      • Ankara、土耳其(türkiye)、06010
        • Research Site
      • Mersin、土耳其(türkiye)、33240
        • Research Site
      • Barretos、巴西、14784-057
        • Research Site
      • Brasília、巴西、70200-730
        • Research Site
      • Florianópolis、巴西、88034-000
        • Research Site
      • São Paulo、巴西、01323-903
        • Research Site
      • Teresina、巴西、64049-200
        • Research Site
      • Bunkyō City、日本、113-8603
        • Research Site
      • Chiba、日本、260-0877
        • Research Site
      • Chūōku、日本、104-0045
        • Research Site
      • Fukuoka、日本、812-8582
        • Research Site
      • Hidaka-shi、日本、350-1298
        • Research Site
      • Hiroshima、日本、734-8551
        • Research Site
      • Hiroshima、日本、730-8518
        • Research Site
      • Iwakuni-shi、日本、740-8510
        • Research Site
      • Kashiwa、日本、277-8577
        • Research Site
      • Kitaadachi-gun、日本、362-0806
        • Research Site
      • Kobe、日本、650-0017
        • Research Site
      • Kumamoto、日本、860-8556
        • Research Site
      • Kōtoku、日本、135-8550
        • Research Site
      • Nagoya、日本、464-8681
        • Research Site
      • Niigata、日本、951-8566
        • Research Site
      • Osakasayama-shi、日本、589-8511
        • Research Site
      • Sapporo、日本、003-0804
        • Research Site
      • Sendai、日本、980-8574
        • Research Site
      • Sendai、日本、980-0873
        • Research Site
      • Wakayama、日本、641-8510
        • Research Site
      • Yokohama、日本、241-8515
        • Research Site
      • Bangkok、泰国、10400
        • Research Site
      • Bangkoknoi、泰国、10700
        • Research Site
      • Banphaeo、泰国、74120
        • Research Site
      • Dusit、泰国、10300
        • Research Site
      • Hat Yai、泰国、90110
        • Research Site
      • Muang、泰国、50200
        • Research Site
      • Muang、泰国、40002
        • Research Site
      • Ratchathewi、泰国、10400
        • Research Site
    • Arizona
      • Tucson、Arizona、美国、85724
        • Research Site
    • California
      • Duarte、California、美国、91010
        • Research Site
      • Glendale、California、美国、91204
        • Research Site
      • Los Angeles、California、美国、90089
        • Research Site
    • Colorado
      • Lone Tree、Colorado、美国、80124
        • Research Site
    • District of Columbia
      • Washington D.C.、District of Columbia、美国、20007
        • Research Site
    • Florida
      • Jacksonville、Florida、美国、32224
        • Research Site
      • St. Petersburg、Florida、美国、33709
        • Research Site
    • Illinois
      • Chicago、Illinois、美国、60637
        • Research Site
      • Evanston、Illinois、美国、60201
        • Research Site
      • Zion、Illinois、美国、60099
        • Research Site
    • Kansas
      • Kansas City、Kansas、美国、66160
        • Research Site
    • Kentucky
      • Lexington、Kentucky、美国、40503
        • Research Site
    • Maryland
      • Baltimore、Maryland、美国、21237
        • Research Site
    • Michigan
      • Farmington Hills、Michigan、美国、48334
        • Research Site
      • Grand Rapids、Michigan、美国、49503
        • Research Site
    • Minnesota
      • Minneapolis、Minnesota、美国、55407
        • Research Site
    • Montana
      • Billings、Montana、美国、59102
        • Research Site
    • Nebraska
      • Omaha、Nebraska、美国、68130
        • Research Site
    • New York
      • East Syracuse、New York、美国、13057
        • Research Site
      • Mineola、New York、美国、11501
        • Research Site
      • New York、New York、美国、10016
        • Research Site
      • New York、New York、美国、10065
        • Research Site
    • Oregon
      • Portland、Oregon、美国、97239
        • Research Site
    • Pennsylvania
      • Bethlehem、Pennsylvania、美国、18015
        • Research Site
      • Philadelphia、Pennsylvania、美国、19107
        • Research Site
      • Pittsburgh、Pennsylvania、美国、15212
        • Research Site
    • Tennessee
      • Knoxville、Tennessee、美国、37920
        • Research Site
      • Memphis、Tennessee、美国、38120
        • Research Site
      • Nashville、Tennessee、美国、37203
        • Research Site
    • Texas
      • Austin、Texas、美国、78745
        • Research Site
      • Dallas、Texas、美国、75231
        • Research Site
      • Houston、Texas、美国、77030
        • Research Site
      • San Antonio、Texas、美国、78217
        • Research Site
    • Virginia
      • Fairfax、Virginia、美国、22031
        • Research Site
    • Washington
      • Seattle、Washington、美国、98104
        • Research Site
    • Wisconsin
      • Madison、Wisconsin、美国、53792
        • Research Site
      • Hanoi、越南、100000
        • Research Site
      • Ho Chi Minh City、越南、700000
        • Research Site
      • Hà Nội、越南、100000
        • Research Site
      • Vinh、越南、460000
        • Research Site
      • Hong Kong、香港、999077
        • Research Site
      • Kuala Lumpur、马来西亚、59100
        • Research Site
      • Kuala Lumpur、马来西亚、50586
        • Research Site
      • Kuching、马来西亚、93586
        • Research Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Histologically documented treatment-naive Stage I (T < 4 cm, AJCC 8th ed) adenocarcinoma NSCLC
  2. Complete surgical resection (R0) of the primary NSCLC
  3. Unequivocal no evidence of disease at post-surgical
  4. Pre-surgical ctDNA-positive result (Stage IA or IB) OR presence of at least one high-risk pathological feature (visceral pleural invasion (VPI), lymphovascular invasion (LVI), high-grade histology) (Stage IB only)
  5. ECOG of 0 or 1, life expectancy of > 6 months and complete recovery after surgery
  6. Adequate bone marrow reserve and organ function

Exclusion Criteria:

  1. Sensitizing EGFR mutation and/or ALK alteration
  2. History of non-infectious ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
  3. Significant pulmonary function compromise
  4. History of another primary malignancy within 3 years (with exceptions)
  5. Any evidence of severe or uncontrolled systemic diseases, including but not limited to bleeding diseases, active infection and cardiac disease
  6. Active or prior documented autoimmune or inflammatory disorders (with exceptions)
  7. Active infection with tuberculosis, hepatitis B or C virus, hepatitis A, or known HIV infection that is not well controlled
  8. History of active primary immunodeficiency
  9. Clinically significant corneal disease

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Dato-DXd + rilvegostomig

Participants in the Dato-DXd in combination with rilvegostomig group will receive Dato-DXd and rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W).

Datopotamab Deruxtecan IV (intravenous)

其他名称:
  • 拿督-DXd,DS-1062a

Rilvegostomig IV (intravenous)

其他名称:
  • AZD2936
实验性的:Rilvegostomig

Participants in the rilvegostomig monotherapy group will receive rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W).

Rilvegostomig IV (intravenous)

其他名称:
  • AZD2936
有源比较器:Standard of Care (SoC)

Patients in SoC group will undergo observation or will receive Investigator's Choice of Chemotherapy (ICC).

Carboplatin IV (intravenous), Active Comparator

Cisplatin IV (intravenous), Active Comparator

Etoposide IV (intravenous), Active Comparator

Pemetrexed IV (intravenous), Active Comparator

Vinorelbine IV (intravenous), Active Comparator

UFT Oral route of administration, Active Comparator

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Disease-Free Survival (DFS) using BICR in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
大体时间:From date of randomisation up to approximately 10 years.

The analysis will include all randomised participants as randomised. All events will be included, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy.

The measure of interest is the HR of DFS.

Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components.

From date of randomisation up to approximately 10 years.

次要结果测量

结果测量
措施说明
大体时间
Overall Survival (OS) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
大体时间:From date of randomisation up to approximately 10 years.

The analysis will include all randomised participants as randomised. All deaths will be included, regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy.

The measure of interest is the HR of OS.

Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components.

From date of randomisation up to approximately 10 years.
Participant-reported physical function in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
大体时间:Measured at weeks 12, 24 and 48.

The analysis will include all randomised participants as randomised. The physical function will be measured by the PROMIS SF PF 8c. Data from PROMIS SF PF 8c will capture participants' perceived ability to perform specific activities from daily life and will be scored on a 5-point rating scale.

The measure of interest will be the between treatment group difference in adjusted mean in physical function scores.

Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components.

Measured at weeks 12, 24 and 48.
Participant-reported GHS/QoL in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
大体时间:Measured at weeks 12, 24 and 48.

The analysis will include all randomised participants as randomised. The GHS/QoL scores will be measured by the GHS/QoL scale from EORTC IL172.

The measure of interest will be the between treatment group difference in adjusted mean in GHS/QoL scores.

Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components.

Measured at weeks 12, 24 and 48.
Pharmacokinetics (PK)
大体时间:Up to 30 or 90 days post-last dose of study intervention.

Concentration of Dato-DXd, total anti-TROP2 antibody, and MAAA-1181a (payload deruxtecan) in plasma or serum.

Up to 30 or 90 days post-last dose of study intervention.
Pharmacokinetics (PK)
大体时间:Up to 30 or 90 days post-last dose of study intervention.

Concentration of rilvegostomig in plasma or serum.

Up to 30 or 90 days post-last dose of study intervention.
Pharmacokinetics (PK)
大体时间:Up to 30 or 90 days post-last dose of study intervention.

PK parameters (peak and through concentrations).

Up to 30 or 90 days post-last dose of study intervention.
Immunogenicity
大体时间:Up to 30 or 90 days post-last dose of study intervention.

Presence of ADAs for Dato-DXd and rilvegostomig (confirmatory results: titres and neutralising antibodies for confirmed positive samples).

Up to 30 or 90 days post-last dose of study intervention.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

合作者

调查人员

  • 首席研究员:David Jones, MD、Memorial Sloan Kettering Cancer Center, New York, United States of America
  • 首席研究员:Enriqueta Felip, MD、Vall d'Hebron Hospital, Barcelona, Spain

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年10月15日

初级完成 (实际的)

2026年7月10日

研究完成 (估计的)

2027年3月31日

研究注册日期

首次提交

2024年8月7日

首先提交符合 QC 标准的

2024年8月19日

首次发布 (实际的)

2024年8月21日

研究记录更新

最后更新发布 (实际的)

2026年9月23日

上次提交的符合 QC 标准的更新

2026年9月22日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.

All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD 共享时间框架

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.

For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD 共享访问标准

When a request has been approved, AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool.

Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD 共享支持信息类型

  • 研究方案
  • 树液

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅